Sun Pharmaceutical Industries Limited — Updates, 22-05-2026: General Updates

Sun Pharma posted strong Q4 sales of ₹14,560 Cr (+13.6%) & PAT of ₹2,714 Cr (+26.2%). Full-year sales hit ₹58,220 Cr. Board proposed ₹5 final dividend (total ₹16/share). Strategic Organon acquisition ($11.75B) announced. US Innovative Meds crossed $1B, India market share gained 0.3%.